Gilead Sciences | GILD - Current Assets


Gilead Sciences reported $16.55B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
ALKERMES USD 1.58B 57.83M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amgen USD 34.36B 598M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Eli Lilly USD 65.26B 591M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Moderna USD 5.82B 45M Jun/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 33.21B 1.68B Sep/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
United Therapeutics USD 2.88B 603.5M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026